SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-22-189496
Filing Date
2022-07-07
Accepted
2022-07-07 16:34:55
Documents
12
Period of Report
2022-06-09
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K/A d718066d8ka.htm   iXBRL 8-K/A 33170
  Complete submission text file 0001193125-22-189496.txt   160202

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA clvs-20220609.xsd EX-101.SCH 2878
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20220609_lab.xml EX-101.LAB 18702
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20220609_pre.xml EX-101.PRE 11710
6 EXTRACTED XBRL INSTANCE DOCUMENT d718066d8ka_htm.xml XML 4094
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-35347 | Film No.: 221072008
SIC: 2834 Pharmaceutical Preparations